Cancer Immunotherapy regulation by antibodies
Received Date: Feb 28, 2023 / Published Date: Mar 28, 2023
Abstract
Radio-immunotherapy with 131I-labelled and 90Y-labelled CD20 conjugates has also shown improved response rates and progression-free survival in patients with NHL. Interestingly, antibody drug or antibody toxin conjugates have been shown to have high potency in haematological malignancies, and there have been two approved by the FDA, gemtuzumab ozogamicin in elderly patients with CD33-positive AML and, more recently, brentuximab vedotin in patients with CD30-positive Hodgkin’s lymphoma. These antibody conjugates have provided the first proof-in-principle for antibodies selectively delivering drug payloads to cancer cells, and a similar approach in patients with advanced ERBB2 positive breast cancer with the antibody drug conjugate trastuzumab emtansine.
Citation: Hsu GC (2023) Cancer Treatment Adaptation Based on Prognostic and Predictive Biomarkers. Adv Cancer Prev 7: 157.
Copyright: © 2023 Hsu GC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Conferences
London, UK
Vancouver, Canada
Toronto, Canada
Recommended Journals
黑料网 Journals
Article Usage
- Total views: 531
- [From(publication date): 0-2023 - Nov 25, 2024]
- Breakdown by view type
- HTML page views: 464
- PDF downloads: 67
